Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Morrison & Foerster represented Krystal Biotech, Inc. in its $200 million common stock offering at $75 per share. Goldman Sachs & Co. LLC, BofA Securities, Cowen, and William Blair acted as joint book-running managers for the offering. Chardan acted as lead manager for the offering.

MoFo Advises Krystal Biotech on $200 Million Common Stock Offering

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Morrison & Foerster represented Krystal Biotech, Inc. in its $200 million common stock offering at $75 per share. Goldman Sachs & Co. LLC, BofA Securities, Cowen, and William Blair acted as joint book-running managers for the offering. Chardan acted as lead manager for the offering.Krystal (NASDAQ: KRYS) is a clinical-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. It recently released positive topline results from the GEM-3 pivotal trial of its leading product candidate VYJUVEK™ in patients with dystrophic epidermolysis bullosa.The MoFo deal team was led by San Francisco corporate senior counsel John Campbell and included corporate associates John Hensley, Jonathan Burr, and Joel Todd. Partner Jim Mullen and associate Bu Yin provided intellectual property counsel on the matter. MoFo has represented the company in corporate and intellectual property matters since its inception in 2016.Read more about the offering in <a href="https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering" rel="noopener noreferrer" target="_blank">Krystal</a>'s press release.

MoFo Advises Krystal Biotech on $200 Million Common Stock Offering

Sign Up

John W. Campbell

Senior Counsel

John Hensley

Partner

Jonathan Burr

Associate

Joel Todd

Bu Yin

Corporate Finance | Capital Markets